City

Bethesda (1)

Guangzhou (1)

Shanghai (1)

Overall Status

Recruiting (2)

Not yet recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID) (1)

Second Affiliated Hospital of Guangzhou Medical University (1)

Shanghai Zhongshan Hospital (1)

Collaborator

Guangdong Zhaotai InVivo Biomedicine Co. Ltd. (1)

Intervention

pd-l1 antibody combined with ctla-4 antibody (1)

tils and car-tils targeting her2, mesothelin, psca, muc1, lewis-y, gpc3, axl, egfr, claudin18.2/6, ror1, gd1, or b7-h3 (1)

Study Documents

Intervention Type

biological (1)

drug (1)

Funder Type

Other (2)

NIH (1)

Study Type

Interventional (2)

Observational (1)

ctla4

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Novel Genetic Disorders of the Immune System

Recruiting

PI3KCD
+3 more

Bethesda, Maryland

National Institutes of Health Clinical Center

Feb 2, 2023

Liver Cancer, Lung Cancer, Breast Cancer Trial in Guangzhou (TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y,

Recruiting

Liver Cancer
+7 more

TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3

Guangzhou, China

Second Affiliated Hospital of Guangzhou Medical University

Apr 9, 2021

Cholangiocarcinoma, Intrahepatic, PD-L1, CTLA4 Trial in Shanghai (PD-L1 antibody combined with CTLA-4 antibody)

Not yet recruiting

Cholangiocarcinoma, Intrahepatic
+2 more

PD-L1 antibody combined with CTLA-4 antibody

Shanghai, China

Zhongshan hospital

Nov 17, 2020